Table 4.
Subgroup analysis; Concomitant of anti-hypertensive drugs.
| Subgroup | Non-responders and responders | Total | P-value | ||
|---|---|---|---|---|---|
| N | R | ||||
| Concomitant anti-hypertensive (−) | (N = 5) | (N = 4) | (N = 9) | ||
| Age | 0.3758 | ||||
| N (missing) | 5 (0) | 4 (0) | 9 (0) | ||
| Mean (SD) | 61.4 (17.49) | 71.3 (12.45) | 65.8 (15.43) | ||
| Median (IQR) | 66.0 (47.0, 72.0) | 75.5 (64.0, 78.5) | 72.0 (53.0, 76.0) | ||
| Range | 40.0, 82.0 | 53.0, 81.0 | 40.0, 82.0 | ||
|
| |||||
| Concomitant anti-hypertensive (+) | (N = 14) | (N = 9) | (N = 23) | ||
| Age | 0.00021 | ||||
| N (missing) | 14 (0) | 9 (0) | 23 (0) | ||
| Mean (SD) | 49.9 (8.66) | 67.4 (10.13) | 56.7 (12.60) | ||
| Median (IQR) | 49.0 (43.0, 54.0) | 72.0 (61.0, 73.0) | 54.0 (47.0, 67.0) | ||
| Range | 39.0, 67.0 | 52.0, 84.0 | 39.0, 84.0 | ||